Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11032356 | 0.84 | CA1 (0.40) | CA1CA2CHRNA7 | |
| SCHEMBL31535325 | 0.83 | CA1 (0.50) | CA1CA2 | |
| SCHEMBL24572139 | 0.81 | CHRNA7 (0.33) | CA1CA2CHRNA7 | |
| SCHEMBL363726 | 0.79 | TP53 (0.48) | — | |
| SCHEMBL31443396 | 0.79 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL68733 | 0.79 | EPHX2 (0.42) | CHRNA7 | |
| SCHEMBL695370 | 0.77 | KDM4E (0.44) | GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL928103 | 0.77 | TP53 (0.47) | GNAI3GNAO1GNAI1 | |
| SCHEMBL5524296 | 0.76 | CA2 (0.48) | CA1CA2 | |
| SCHEMBL13621140 | 0.76 | MEN1 (0.48) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-4504179-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | Corbus Pharmaceuticals, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119325378-A | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof | 柯巴斯医药有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2022111634-A1 | HETEROARYLQUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS | 成都赛璟生物医药科技有限公司 | 2022-06-02 | — | — | WO | disclosed |
| CN-110003214-B | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-1343503-B1 | HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | CA1 4654/4885CA2 4564/4885CHRNA7 500/4885 |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | FABP4, GPR119, SRM | CA1 4320/4885CA2 2597/4885CHRNA7 4502/4885 |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | CA1 3715/4885CA2 2478/4885CHRNA7 4287/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | CA1 1399/4885CA2 315/4885CHRNA7 508/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | CA1 1399/4885CA2 315/4885CHRNA7 508/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CA1 3756/4885CA2 2490/4885CHRNA7 4217/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | CA1 3756/4885CA2 2490/4885CHRNA7 4217/4885 |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CYP4F3, HCCS | CA1 848/4885CA2 843/4885CHRNA7 341/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | CA1 4822/4885CA2 4494/4885CHRNA7 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.